This guide explores ASX penny stocks, including their risks and opportunities, trading tips, and five promising shares to watch in 2025.
This article is for informational purposes only and does not constitute investment or trading advice. Please ensure you understand the risks and consider your individual circumstances before trading.
In Australia, many classify penny stocks as those under one Australian dollar per share, while some use the definition loosely to describe any company with smaller share prices.
Penny stock share trading requires a high degree of due diligence, as they represent smaller propositions that usually come with a far higher risk-to-reward ratio. Ensure you have adequate risk management in place before you consider trading penny stocks.
It’s also worth noting that penny stocks can have high market caps if a large number of shares have been issued.
ASX penny stocks are often thinly traded. This means that, unlike the blue-chip shares of the ASX 200, where every stock usually has a wall of potential buyers, there might not always be enough buyer demand when share traders want to sell.
In addition, penny stocks are often loss-making, using any money available to invest in growth. This makes them highly speculative investments. Moreover, they usually receive little to no analyst coverage, making informed trading decisions difficult.
They can also even lack in-depth trading records. And some penny stocks are notorious for diluting stock value by issuing additional shares.
These risk factors mean that for most share traders, penny stocks should only form a small percentage of their portfolio. And for those closer to retirement who are investing over short timeframes, they arguably should be avoided altogether.
Of course, despite these significant risks, ASX penny stocks hold a unique advantage. The right pick can be massively more lucrative than an investment in more established peers.
However, it’s important to be aware of the echo chamber of success. Skyrocketing penny stocks are extremely likely to hit mainstream news, but the success stories are significantly outnumbered by the failures. Moreover, once an ASX penny stock hits the headlines, it's often too late to partake in its success.
But many of the largest blue-chip stocks on the ASX began trading as penny stocks. For example, one of the largest stocks on the ASX, BHP, used to be a penny stock back in 1999. Afterpay was a penny stock as recently as 2017. International market titans Apple and Amazon also once qualified as penny stocks for investors with the foresight and luck to invest early.
We selected these penny stocks based on three main factors:
All the penny stocks on our list are available to share trade directly by buying them on our share trading platform, whereas the following ones can be traded via CFDs:
Company |
Industry |
Share price (15 August 2025) |
Market cap |
Trade the share CFD with us? |
Share trade the stock with us? |
Defence technology and communications |
A$0.445
|
A$49.29 million |
X |
✓ |
|
Healthcare communications |
A$0.37 |
A$129.75 million |
X |
✓ |
|
Construction |
A$0.445 |
A$123.23 million |
✓ |
✓ |
|
Health supplements and infant formula ingredients |
A$0.545 |
A$93.52 million |
✓ |
✓ |
|
Software solutions |
A$0.63 |
A$70.23 million |
✓ |
✓ |
Industry: Defence technology and communications
Market cap: A$49.29 million1
Share price (15 August 2025): A$0.445
HighCom operates locally and internationally, with three primary business segments:
The company is undergoing a significant restructuring phase, focused on returning to profitability and positioning for future growth. HighCom is streamlining operations, optimising its service delivery models and concentrating on higher-margin business segments. It’s particularly emphasising its cloud-based solutions and recurring revenue streams.
Highlights:
Industry: Healthcare communications
Market cap: A$129.75 million4
Share price (15 August 2025): A$0.37
Austco Healthcare specialises in healthcare communication and workflow management solutions designed to improve patient care and operational efficiency. Its core product portfolio includes the Tacera platform, an integrated nurse call and communication system that connects patients, nurses and healthcare staff through clever alert management technology.
The company also provides staff duress systems (giving people the ability to call for emergency help discreetly), patient entertainment solutions and mobile communication platforms.
Additionally, Austco offers comprehensive maintenance services, system upgrades and 24/7 technical support to ensure the continuous operation of critical healthcare comms.
Highlights:
Industry: Construction
Market cap: A$123.23 million7
Share price (15 August 2025): A$0.445
Alfabs has built its reputation over several decades, serving the construction, architectural and industrial sectors. Originally focused on standard aluminium products, it’s evolved to become a comprehensive solutions provider for complex architectural and industrial projects.
The company’s product portfolio includes custom aluminium windows, doors, curtain walling systems, structural glazing and specialised industrial fabrications.
It serves multiple markets, including commercial construction, residential developments, infrastructure projects and industrial facilities.
Alfabs combines traditional fabrication techniques with modern CAD design capabilities and precision manufacturing equipment.
Highlights:
Industry: Health supplements and infant formula ingredients
Market cap: A$93.52 million9
Share price (15 August 2025): A$0.545
Clover Corporation was established in 1998 as a specialised health ingredients company, focused on developing and manufacturing omega-3 fatty acid products. It’s evolved from a small Australian startup to become a globally recognised producer of high-quality nutritional oils, particularly docosahexaenoic acid (DHA) and arachidonic acid (ARA) for infant formula.
DHA and ARA oils are essential for infant brain and eye development, and Clover supplies these to major infant formula manufacturers globally.
Its products serve critical markets in addition to infant formula, including medical foods, functional foods and dietary supplements, with operations spanning Australia, Europe, Asia and the Americas.
Highlights:
Industry: Software solutions
Market cap: A$70.23 million11
Share price (15 August 2025): A$0.63
Reckon became well-known for bringing QuickBooks to the Australian market through a licensing partnership with Intuit. Over the years, it’s evolved from a single-product company to a diversified business and legal software provider, expanding through acquisitions and product development to service various professional service markets.
It’s a software-as-a-service (SaaS) provider, specialising in business management solutions for small to medium enterprises and professional services firms. Its product portfolio includes cloud-based accounting software, practice management solutions for legal and accounting firms and document management systems. The company's flagship products are:
Highlights:
This is the idea that if a share price falls between 7% and 8% below what you paid for it, you should sell it.
If a company keeps spending more than it earns, and share traders sell their shares, theoretically, a stock’s price can hit 0.
Some analysts recommend buying a substantial number of a penny stock’s shares – its low price means the full investment won’t total too much, but if the value increases, the shareholding can grow substantially. Of course, this is a risky strategy, as is any when purchasing penny stocks, as these are high-risk, high-reward shares.
This information has been prepared by IG, a trading name of IG Australia Pty Ltd. In addition to the disclaimer below, the material on this page does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. IG accepts no responsibility for any use that may be made of these comments and for any consequences that result. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. Any research provided does not have regard to the specific investment objectives, financial situation and needs of any specific person who may receive it. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication. Although we are not specifically constrained from dealing ahead of our recommendations we do not seek to take advantage of them before they are provided to our clients.